BSE: CHOKSILA · Healthcare Service Provider
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Growth · Profitability · Valuation · Strength · Conviction
Choksi Laboratories Limited provides comprehensive quality control, analytical testing, and calibration services across diverse sectors including pharmaceuticals, food, and environmental monitoring. Headquartered in Indore, the company operates an accredited laboratory network to ensure regulatory compliance for both domestic and multinational clients.
The company generates revenue by providing fee-based testing, inspection, and certification services to industrial clients requiring quality assurance and regulatory adherence. It leverages its NABL-accredited laboratory infrastructure to offer specialized technical consultancy and instrument calibration.
Growth is driven by increasing demand for stringent quality control in the pharmaceutical and food sectors, alongside expanding requirements for environmental monitoring. The company aims to leverage its technical expertise to capture a larger share of the Indian testing, inspection, and certification market.
Unlock AI insights, financials, peers and live data on Choksi Laboratories Ltd. and 5,000+ companies — free.
REVENUE
₹46 Cr
TTM · standalone
NET PROFIT
₹2 Cr
TTM · standalone
EPS
₹2.82
TTM · standalone
RETURN ON EQUITY
8.2%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
13.9%
TTM · standalone
P/E
39.9x
Q4 FY26 · standalone
EV/EBITDA
8.6x
Q4 FY26 · standalone
EBITDA MARGIN
26.8%
TTM · standalone
NET PROFIT MARGIN
8.0%
Q4 FY26 · standalone
DEBT TO EQUITY
1.2x
Q4 FY26 · standalone
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Choksi Laboratories Ltd.CHOKSILA | ₹103 Cr | 52.43 | 10.79 | 10.1% | 26.8% | 8.2% | 13.9% | -26.1% |
Krsnaa Diagnostics Ltd.KRSNAA | ₹1,830 Cr | 18.76 | 8.80 | 10.2% | 32.5% | 10.5% | 13.3% | -28.5% |
Suraksha Diagnostic Ltd.SURAKSHA | ₹1,772 Cr | 48.60 | 16.73 | 22.5% | 32.7% | 15.8% | 18.6% | +14.0% |
3B BlackBio Dx Ltd3BBLACKBIO | ₹1,237 Cr | 20.61 | 14.59 | 41.9% | 58.0% | 21.2% | 26.3% | +0.5% |
One Global Service Provider LimitedONEGLOBAL | ₹1,068 Cr | — | — | — | 19.0% | — | — | +114.9% |
Gaudium IVF and Women Health LimitedGAUDIUMIVF | ₹886 Cr | — | — | — | 36.0% | — | — | — |
As of Q4 FY26
Choksi Laboratories Ltd.
BSE: CHOKSILA · Healthcare Service Provider
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Growth · Profitability · Valuation · Strength · Conviction
Choksi Laboratories Limited provides comprehensive quality control, analytical testing, and calibration services across diverse sectors including pharmaceuticals, food, and environmental monitoring. Headquartered in Indore, the company operates an accredited laboratory network to ensure regulatory compliance for both domestic and multinational clients.
The company generates revenue by providing fee-based testing, inspection, and certification services to industrial clients requiring quality assurance and regulatory adherence. It leverages its NABL-accredited laboratory infrastructure to offer specialized technical consultancy and instrument calibration.
Growth is driven by increasing demand for stringent quality control in the pharmaceutical and food sectors, alongside expanding requirements for environmental monitoring. The company aims to leverage its technical expertise to capture a larger share of the Indian testing, inspection, and certification market.
Unlock AI insights, financials, peers and live data on Choksi Laboratories Ltd. and 5,000+ companies — free.
REVENUE
₹46 Cr
TTM · standalone
NET PROFIT
₹2 Cr
TTM · standalone
EPS
₹2.82
TTM · standalone
RETURN ON EQUITY
8.2%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
13.9%
TTM · standalone
P/E
39.9x
Q4 FY26 · standalone
EV/EBITDA
8.6x
Q4 FY26 · standalone
EBITDA MARGIN
26.8%
TTM · standalone
NET PROFIT MARGIN
8.0%
Q4 FY26 · standalone
DEBT TO EQUITY
1.2x
Q4 FY26 · standalone
As of Q4 FY26